Physician profile
Ari J Ciment
NPI 1932261542
$24,146.92
in general payments reported to CMS, 2019-2025
29 companies · $4,082 in 2025
The $4,082 reported for 2025 was more than what 86% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,384 · 2020: $2,771 · 2021: $514 · 2022: $3,908 · 2023: $9,452 · 2024: $1,035 · 2025: $4,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $3,211 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,203.50 |
| Food and Beverage | $3,210.77 |
| Education | $154.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vapotherm INC | $14,551.94 | 2021-2025 | Vapotherm |
| Mylan Specialty L.P. | $4,649.88 | 2019-2023 | Yupelri |
| Glaxosmithkline, LLC. | $1,573.53 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $622.32 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Actelion Pharmaceuticals US, INC. | $571.33 | 2021-2025 | Uptravi, Opsumit |
| Abbvie INC. | $320.16 | 2021-2023 | Avycaz, Dalvance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $293.51 | 2019-2025 | Jascayd, Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $242.65 | 2019-2024 | Glassia |
| Amgen INC. | $164.37 | 2023-2025 | Tezspire |
| Grifols USA, LLC | $143.33 | 2019-2023 | Prolastin-C Liquid |
| Genzyme Corporation | $140.17 | 2021-2025 | |
| Insmed, INC. | $138.29 | 2024-2025 | Brinsupri, Arikayce |
| Janssen Pharmaceuticals, INC | $98.39 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.94 | 2020-2023 | |
| Pfizer INC. | $77.87 | 2019-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $75.35 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $65.15 | 2023 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| United Therapeutics Corporation | $49.86 | 2025 | Tyvaso |
| Regeneron Healthcare Solutions, INC. | $48.15 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $43.52 | 2019-2025 | Winrevair |
| Ani Pharmaceuticals, INC. | $30.54 | 2023 | Purified Cortrophin Gel |
| Inogen, INC. | $25.24 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Sunovion Pharmaceuticals INC. | $24.62 | 2019 | |
| Electromed, INC. | $22.83 | 2025 | Smartvest |
| Philips North America LLC | $21.88 | 2025 | Vest Therapy Und |
| Eagle Pharmaceuticals, INC. | $20.52 | 2023 | |
| Genentech USA, INC. | $16.74 | 2019 | |
| Celgene Corporation | $15.48 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ari Ciment listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.